Economics of vaccines revisited

Maarten J. Postma*, Baudouin A. Standaert

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Performing a total health economic analysis of a vaccine newly introduced into the market today is a challenge when using the conventional cost-effectiveness analysis we normally apply on pharmaceutical products. There are many reasons for that, such as: the uncertainty in the total benefit (direct and indirect) to be measured in a population when using a cohort model;(1) appropriate rules about discounting the long-term impact of vaccines are absent jeopardizing therefore their value at the initial investment;(2) the presence of opposite contexts when introducing the vaccine in developed vs. the developing world with high benefits, low initial health care investment for the latter vs. marginal benefit and high cost for the former; with a corresponding paradox for the vaccine becoming very cost-effective in low income countries but rather medium in middle low to high middle income countries;(3) and the type of trial assessment for the newer vaccines is now often performed with immunogenicity reaction instead of clinical endpoints which still leaves questions on their real impact and their head-to-head comparison.(4

Original languageEnglish
Pages (from-to)1139-1141
Number of pages3
JournalHuman vaccines & immunotherapeutics
Volume9
Issue number5
DOIs
Publication statusPublished - 1-May-2013

Keywords

  • health economics
  • new approaches
  • modeling
  • cost-effectiveness
  • perspectives
  • COST-EFFECTIVENESS
  • ROTAVIRUS VACCINATION
  • HUMAN-PAPILLOMAVIRUS
  • PANDEMIC INFLUENZA
  • IMPACT
  • BENEFITS
  • OUTCOMES
  • MODELS
  • UK

Cite this